Aurevia

Press release

Aurevia Appoints Sapna Hornyak as Chief Executive Officer to Lead Next Phase of Growth

[Stockholm, Sweden, November 24, 2026] – Today Aurevia announced the appointment of Sapna Hornyak as Chief Executive Officer (CEO). She succeeds Juha-Pekka Nuutinen, who has served as Aurevia's CEO since the company was formed in 2025 and following the demerger from Labquality. Juha-Pekka will continue as CEO of Labquality while supporting Aurevia's continued growth and long-term development as Chairman of the Board.

The transition marks a new strategic chapter following the 2025 demerger of Aurevia and Labquality, which established a clear direction and strong foundation for Aurevia's growth. Aurevia is a comprehensive life sciences consulting and CRO partner, supporting customers from early development through post-market activities. Through its combination of expertise in quality assurance, regulatory affairs, clinical research, and market access, the company helps clients navigate complexity, manage risk, and bring innovative healthcare solutions to market with confidence.

Sapna brings more than 20 years of international leadership experience from the global life sciences industry. Most recently, she served as CEO of Avania, one of the world's leading medical technology-focused CROs. Prior to that, she held several executive leadership positions within clinical CROs, including Chiltern and Theorem Clinical Research, building expertise in clinical and regulatory services, operational excellence and strategic partnerships across the medical device, diagnostics, and pharmaceutical sectors.

"Throughout my career, I have been passionate about helping life sciences companies bring innovative healthcare solutions to patients faster and more efficiently," said Sapna. " Aurevia's success has been built on deep expertise, trusted relationships, and a shared commitment to client outcomes. I look forward to working with our colleagues and customers to continue building a life sciences consultancy with the scale, expertise, and agility needed to navigate an increasingly complex regulatory and clinical landscape."

Juha-Pekka Nuutinen, who has led Aurevia since its formation in 2025 and will continue as CEO of Labquality while serving on Aurevia's Board, adds:

"It has been a privilege to lead Aurevia and work alongside such talented colleagues and customers. Together, we have built a strong foundation, expanded our services and geographic reach, and established a company uniquely positioned to support life sciences innovators throughout the product lifecycle. As I move into a broader role on the Board, I am confident that Sapna's leadership experience, global perspective, and deep understanding of the industry make her the ideal person to lead Aurevia into its next chapter."

Our experienced leadership team remains firmly in place, and your existing contacts at Aurevia are unchanged. Ulrika Hammarström and Anna-Karin Alm continue to serve on Aurevia's Executive Leadership Team and remain available as senior points of contact for our partners. Together, we remain committed to providing the same high level of expertise, collaboration, and service that you have come to expect from Aurevia.

Under Sapna's leadership, Aurevia will continue to focus on delivering high-quality expertise, strengthening customer partnerships, expanding service capabilities, and supporting innovation across the life sciences sector.

About Aurevia
Aurevia is a life sciences consulting and contract research organization (CRO) partner providing expertise in quality assurance, regulatory affairs, and clinical research to pharmaceutical, biotechnology, medical device, and IVD companies. Aurevia was formed in 2025 through a demerger from Labquality, bringing together the complementary expertise of organizations such as Scandinavian CRO and QAdvis to create a company with a dedicated strategic focus on supporting life sciences innovators.

Aurevia supports customers throughout the product lifecycle, from development and regulatory strategy to clinical execution, market access, and post-market compliance. With deep scientific expertise and strong customer focus, Aurevia helps organizations navigate complexity, accelerate innovation, and bring safe and effective healthcare solutions to market.



About Sapna Hornyak, CEO of Aurevia
Sapna has more than 20 years of leadership experience across the global life sciences industry, with deep expertise in clinical research, medical devices, diagnostics, and pharmaceuticals. Throughout her career, she has led international organizations through growth, transformation, and operational excellence helping life sciences companies bring innovative healthcare solutions to market.

Prior to joining Aurevia, Sapna served as CEO of Avania, a leading global CRO focused on medical technology. She has also held several executive leadership positions at Chiltern and Theorem Clinical Research, with responsibilities spanning clinical development, global operations, business strategy, and commercial growth.

Known for building high-performing teams and strong customer partnerships, Sapna combines strategic vision with extensive industry expertise. She is passionate about partnering with life sciences organizations to accelerate innovation, improve patient access, and deliver better health outcomes.

Sapna holds a Master of Science in Biomedical Diagnostics from Arizona State University and an MBA from the University of Pittsburgh.

Media Contact
Christina Ninalga Stålberg
Marketing Manager at Aurevia
christina.ninalga.stalberg@aurevia.com
https://www.aurevia.com/
+46 (0) 18 10 05 50